BRD4 and neoplasm: Compared to OPT-0139 used alone, the combination of cisplatin and OPT-0139 displayed a greater decrease in BRD4 expression and tumor cell viability; cell viability decreased by about 40% with the use of cisplatin alone and by almost 60% with the combined use of OPT-0139 and cisplatin (Figure 7A).